Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC
Part of paid clinical trials in New Haven, Connecticut.
- Sponsor
- Yale University
- Study ID
- NCT07066189
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Exercise and Medical Nutrition — BEHAVIORAL10, 30-minute sessions spread out over the course of their neoadjuvant therapy and in the weeks leading up to surgery. On weeks counseling is not scheduled an exercise session will be observed.
Study Details
The purpose of this study is to examine whether a nutrition and exercise program can improve pathologic complete response (pCR) in women with triple-negative breast cancer (TNBC) receiving chemo-immunotherapy before surgery. Pathologic complete (pCR) response means that no cancer in the breast is seen after chemotherapy.
Key Dates
- Start date
- Oct 17, 2025
- Status verified
- Oct 2025
- Primary completion
- Oct 31, 2029
- Completion
- Oct 31, 2029
Study Design
- Enrollment
- 160 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Exercise and Medical NutritionWomen randomized to the intervention will receive 10, 30-minute sessions spread out over the course of their neoadjuvant therapy and in the weeks leading up to surgery. In weeks in which one of the 10 counseling sessions is not scheduled the interventionist will observe the participant in an exercise session via zoom, or check in with the participant by phone regarding their exercise. The intervention will continue until the day prior to the last chemotherapy infusion.
- No Intervention: Usual careContact limited to study assessments.
Primary Outcome Measure
Pathologic Complete Response (pCR) [ Time Frame: Post breast cancer surgery, an average of 6 months ]
Central Contacts
- Melinda Irwin203-785-6392
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Yale University | New Haven | Connecticut | 06511 |
Find similar trials in New Haven, CT
By condition
By specialty
By research site
Related Studies
- Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of DiseasePHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · San Carlos, California
- Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBCPHASE2 · Recruiting · Dana-Farber Cancer Institute · Stamford, Connecticut
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · Irvine, California
- Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)PHASE3 · Recruiting · Gilead Sciences · Birmingham, Alabama